Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

Summary

This is a non-inferiority, open label, randomized trial of women on buprenorphine Medication Assisted Therapy for opioid use disorder in pregnancy.Patients will be randomized to either the long acting monthly subcutaneous SublocadeTM or to short acting sublingual Suboxone®.

Timeline

Start

2020-02-21

Primary completion

2020-09-01

Completion

2020-09-01

Outcome

Outcome not reported

Stopped: “closed due to new safety concerns of subcutaneous buprenorphine in pregnant patients”

Drugs

Indications